OPKO Health (NASDAQ:OPK) Sees Unusually-High Trading Volume After Insider Buying Activity

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) saw strong trading volume on Wednesday after an insider bought additional shares in the company. 3,744,040 shares changed hands during mid-day trading, a decline of 8% from the previous session's volume of 4,068,860 shares.The stock last traded at $1.67 and had previously closed at $1.66.

Specifically, CEO Phillip Md Et Al Frost bought 100,000 shares of the company's stock in a transaction that occurred on Tuesday, April 1st. The shares were acquired at an average cost of $1.65 per share, for a total transaction of $165,000.00. Following the acquisition, the chief executive officer now owns 213,751,448 shares in the company, valued at $352,689,889.20. This represents a 0.05 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock in a transaction dated Friday, March 28th. The shares were purchased at an average cost of $1.70 per share, for a total transaction of $255,000.00. Following the completion of the transaction, the chief executive officer now owns 213,651,448 shares of the company's stock, valued at approximately $363,207,461.60. This represents a 0.07 % increase in their position. The disclosure for this purchase can be found here.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price target on shares of OPKO Health in a research note on Wednesday, March 19th. Barrington Research restated an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a report on Wednesday, March 12th. Finally, StockNews.com raised shares of OPKO Health from a "sell" rating to a "hold" rating in a research report on Monday, March 3rd.

OPKO Health Trading Down 2.9 %

The firm has a market cap of $1.01 billion, a P/E ratio of -7.92 and a beta of 1.78. The business's 50-day moving average is $1.69 and its two-hundred day moving average is $1.58. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. As a group, analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of OPK. Wealth Enhancement Advisory Services LLC increased its position in OPKO Health by 75.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after acquiring an additional 12,417 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of OPKO Health by 24.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 753,380 shares of the biotechnology company's stock worth $1,107,000 after acquiring an additional 148,322 shares during the period. Two Sigma Advisers LP boosted its holdings in shares of OPKO Health by 2.3% in the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company's stock valued at $560,000 after acquiring an additional 8,396 shares in the last quarter. Two Sigma Investments LP raised its holdings in OPKO Health by 136.1% during the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock worth $2,422,000 after purchasing an additional 949,671 shares in the last quarter. Finally, ProShare Advisors LLC boosted its stake in OPKO Health by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 91,730 shares of the biotechnology company's stock valued at $135,000 after purchasing an additional 30,182 shares in the last quarter. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.